SG11202003318QA - Products and methods for monitoring adherence to nucleoside reverse transcriptase inhibitor therapy - Google Patents

Products and methods for monitoring adherence to nucleoside reverse transcriptase inhibitor therapy

Info

Publication number
SG11202003318QA
SG11202003318QA SG11202003318QA SG11202003318QA SG11202003318QA SG 11202003318Q A SG11202003318Q A SG 11202003318QA SG 11202003318Q A SG11202003318Q A SG 11202003318QA SG 11202003318Q A SG11202003318Q A SG 11202003318QA SG 11202003318Q A SG11202003318Q A SG 11202003318QA
Authority
SG
Singapore
Prior art keywords
products
methods
reverse transcriptase
nucleoside reverse
transcriptase inhibitor
Prior art date
Application number
SG11202003318QA
Inventor
Giffin Daughtridge
Keith Kardos
Original Assignee
Ursure Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ursure Inc filed Critical Ursure Inc
Publication of SG11202003318QA publication Critical patent/SG11202003318QA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366Apparatus specially adapted for solid-phase testing
    • G01N33/54386Analytical elements
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366Apparatus specially adapted for solid-phase testing
    • G01N33/54386Analytical elements
    • G01N33/54387Immunochromatographic test strips
    • G01N33/54388Immunochromatographic test strips based on lateral flow
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202003318QA 2017-10-13 2018-10-15 Products and methods for monitoring adherence to nucleoside reverse transcriptase inhibitor therapy SG11202003318QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762572126P 2017-10-13 2017-10-13
PCT/US2018/055961 WO2019075487A1 (en) 2017-10-13 2018-10-15 Products and methods for monitoring adherence to nucleoside reverse transcriptase inhibitor therapy

Publications (1)

Publication Number Publication Date
SG11202003318QA true SG11202003318QA (en) 2020-05-28

Family

ID=66101731

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202003318QA SG11202003318QA (en) 2017-10-13 2018-10-15 Products and methods for monitoring adherence to nucleoside reverse transcriptase inhibitor therapy

Country Status (9)

Country Link
US (1) US11795239B2 (en)
EP (1) EP3695225A4 (en)
JP (1) JP2020536588A (en)
KR (1) KR20200086678A (en)
CN (1) CN111727372A (en)
AU (1) AU2018347704A1 (en)
CA (1) CA3079140A1 (en)
SG (1) SG11202003318QA (en)
WO (1) WO2019075487A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3948278A1 (en) * 2019-04-01 2022-02-09 OraSure Technologies, Inc. System and method for detecting therapeutic agents to monitor adherence to a treatment regimen
US20220372171A1 (en) * 2019-09-20 2022-11-24 Abbott Rapid Diagnostics International Unlimited Company Antibody directed against tenofovir and derivatives thereof
US20220196641A1 (en) * 2020-12-18 2022-06-23 Orasure Technologies, Inc. Reagents, methods, and systems for detecting therapeutic agents to monitor adherence to nucleoside reverse transcriptase inhibitor metabolites

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014364A1 (en) * 2002-08-07 2004-02-19 Idenix (Cayman) Limited Substituted phenylindoles for the treatment of hiv
US20110200609A1 (en) * 2002-09-12 2011-08-18 The Regents Of The University Of California Monoclonal antibodies specific for pathological amyloid aggregates common to amyloids formed from proteins of differing sequence
ES2320252T3 (en) * 2004-09-17 2009-05-20 Idenix Pharmaceuticals, Inc. PHOSFOINDOLS AS HIV INHIBITORS.
WO2007103740A2 (en) * 2006-03-01 2007-09-13 Ark Diagnostics Immunoassays, haptens, immunogens and antibodies for anti-hiv therapeutics
CN103261222B (en) 2010-09-10 2017-07-28 医疗免疫有限公司 Antibody derivatives
US20200200735A9 (en) * 2016-02-22 2020-06-25 Ursure, Inc. System and method for detecting therapeutic agents to monitor adherence to a treatment regimen
WO2019018747A1 (en) 2017-07-20 2019-01-24 Trustees Of Boston University Tenofovir detection assay
US20220196641A1 (en) * 2020-12-18 2022-06-23 Orasure Technologies, Inc. Reagents, methods, and systems for detecting therapeutic agents to monitor adherence to nucleoside reverse transcriptase inhibitor metabolites

Also Published As

Publication number Publication date
EP3695225A1 (en) 2020-08-19
CA3079140A1 (en) 2019-04-18
CN111727372A (en) 2020-09-29
WO2019075487A1 (en) 2019-04-18
AU2018347704A1 (en) 2020-05-28
US20200239598A1 (en) 2020-07-30
EP3695225A4 (en) 2021-06-30
KR20200086678A (en) 2020-07-17
US11795239B2 (en) 2023-10-24
JP2020536588A (en) 2020-12-17

Similar Documents

Publication Publication Date Title
IL269462A (en) Mdm2 inhibitors and therapeutic methods using the same
HK1243901A1 (en) Devices and methods for ablation of the skin
EP3160475C0 (en) Substituted nucleosides and nucleotides to treat filoviridae infections
DK3122752T3 (en) 4'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AS HIV REVERSE TRANSCRIPTASE INHIBITORS
HUE059131T2 (en) Therapeutic combinations of a btk inhibitor, a pd-1 inhibitor and/or a pd-l1 inhibitor
PT3286166T (en) Inhibitors of human immunodeficiency virus replication
HK1225617A1 (en) 4’-difluoromethyl substituted nucleoside derivatives as inhibitors of influenza rna replication
EP3352781A4 (en) 4'-substituted nucleoside reverse transcriptase inhibitors and preparations thereof
HK1249497A1 (en) Ebna1 inhibitors and methods using same
HK1254954A1 (en) Lpt-723 and immune checkpoint inhibitor combinations and methods of treatment
PL3125894T3 (en) Prodrugs of hiv reverse transcriptase inhibitors
SG11202003318QA (en) Products and methods for monitoring adherence to nucleoside reverse transcriptase inhibitor therapy
IL267238A (en) Heparanase inhibitors and use thereof
ZA201705530B (en) 6-morpholinyl-2-pyrazolyl-9h-purine derivatives and their use as pi3k inhibitors
SG11201605915WA (en) Furo-3-carboxamide derivatives and methods of use
HK1250028A1 (en) 2-phenyl-6-imidazolyl-pyridine-4-carboxamide derivatives and their use as eaat3 inhibitors
GB201705413D0 (en) Shale hydration inhibitor and method of use
GB2541039B (en) Devices for and methods of diagnosis and/or monitoring dysphagia
PT3107913T (en) Inhibitors of human immunodeficiency virus replication
PT3433257T (en) Alkynyl nucleoside analogs as inhibitors of human rhinovirus
IL267243A (en) Heparanase inhibitors and use thereof
GB201404656D0 (en) Real-time systems and methods for management of alimentation